Results 211 to 220 of about 937,622 (274)

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

open access: yesAllergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud   +14 more
wiley   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres   +19 more
wiley   +1 more source

Carriage of antimicrobial‐resistant E. coli in urban stray cats (Felis catus)

open access: yesAustralian Veterinary Journal, EarlyView.
Antimicrobial resistance (AMR) in Escherichia coli is a growing concern in both human and veterinary medicine, driven by the inappropriate use of antimicrobials. Companion animals may act as community reservoirs and sentinels for antimicrobial‐resistant bacteria due to their close contact with humans and other animals.
JS Kuan, S Mukerji, D Hampson, S Abraham
wiley   +1 more source

Assessment of aminoglycosides and β-lactam resistance genes among uropathogens; a prospective-cross sectional study. [PDF]

open access: yesBMC Urol
Khan J   +8 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Identification of Novel β-Lactam Derivatives as Proteasome Inhibitors for Antitumor Therapy. [PDF]

open access: yesArch Pharm (Weinheim)
Cao Y   +11 more
europepmc   +1 more source

Chemoproteomic discovery of a brain‐penetrant, covalent NLRP3 inhibitor that binds a novel allosteric pocket

open access: yesBritish Journal of Pharmacology, EarlyView.
NLRP3 is a promising inflammatory target, but existing inhibitors lack diversity and brain penetrance, and none are approved. Using chemoproteomics, we discovered a novel series that binds to Cys463 in a previously uncharacterized pocket. Compounds showed nanomolar potency, brain exposure, and in vivo suppression of IL‐1β, supporting neuroinflammatory ...
Donald C. Rogness   +21 more
wiley   +1 more source

Molecular characterization and correlation with β-lactam resistance of penicillin-binding protein2x, 2b, and 1a of <i>Streptococcus pneumoniae</i> in clinical pneumococcal isolates. [PDF]

open access: yesMicrobiol Spectr
Zhang Y   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy